GRADE guidelines: 3. Rating the quality of evidence.
暂无分享,去创建一个
Howard Balshem | Gordon H Guyatt | Jan Brozek | Andrew D Oxman | Holger J Schünemann | Yngve Falck-Ytter | Mark Helfand | Regina Kunz | Joerg Meerpohl | Gunn E Vist | G. Guyatt | A. Oxman | H. Schünemann | G. Vist | J. Brożek | S. Norris | M. Helfand | Y. Falck‐Ytter | R. Kunz | Howard Balshem | J. Meerpohl | Susan Norris | Y. Falck-Ytter
[1] Gerald Gartlehner,et al. [GRADE guidelines: 8. Rating the quality of evidence - indirectness]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.
[2] Gerald Gartlehner,et al. [GRADE guidelines: 7. Rating the quality of evidence - inconsistency]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.
[3] Gerald Gartlehner,et al. [GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.
[4] G. Guyatt,et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. , 2011, Journal of clinical epidemiology.
[5] G. Guyatt,et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. , 2011, Journal of clinical epidemiology.
[6] Gordon H Guyatt,et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. , 2011, Journal of clinical epidemiology.
[7] G. Guyatt,et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). , 2011, Journal of clinical epidemiology.
[8] Gordon H Guyatt,et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.
[9] R. Beyth,et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[10] D. Singer,et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[11] G. Guyatt,et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.
[12] A D Oxman,et al. Randomisation to protect against selection bias in healthcare trials. , 2011, The Cochrane database of systematic reviews.
[13] Paul Glasziou,et al. When are randomised trials unnecessary? Picking signal from noise , 2007, BMJ : British Medical Journal.
[14] D. P. Bentley,et al. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial , 2007, BMJ : British Medical Journal.
[15] Contextualizing medical decisions to individualize care , 2004, Journal of General Internal Medicine.
[16] P. McGettigan,et al. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. , 2006, JAMA.
[17] K. Wood,et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.
[18] Ruth Gilbert,et al. Infant sleeping position and the sudden infant death syndrome: systematic review of observational studies and historical review of recommendations from 1940 to 2002. , 2005, International journal of epidemiology.
[19] Robert W Platt,et al. Feeding effects on growth during infancy. , 2004, The Journal of pediatrics.
[20] A. Charlett,et al. Effectiveness of antibiotics in preventing meningococcal disease after a case: systematic review , 2004, BMJ : British Medical Journal.
[21] J. Douketis,et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor , 2004, Journal of thrombosis and haemostasis : JTH.
[22] F. Song,et al. Evaluating non-randomised intervention studies. , 2003, Health technology assessment.
[23] S. Connolly,et al. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial. , 2003, JAMA.
[24] N. Andrews,et al. Recall bias, MMR, and autism , 2002, Archives of disease in childhood.
[25] G. Guyatt,et al. A systematic review and meta-analysis of studies comparing mortality rates of private for-profit and private not-for-profit hospitals. , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[26] P. Prandoni,et al. Three months vs. one year of oral anticoagulant therapy for idiopathic deep venous thrombosis , 2002 .
[27] H. Bedford,et al. MMR vaccine—worries are not justified , 2001, Archives of disease in childhood.
[28] W. Ageno,et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. , 2001, The New England journal of medicine.
[29] M. Santini,et al. Permanent Cardiac Pacing Versus Medical Treatment for the Prevention of Recurrent Vasovagal Syncope: A Multicenter, Randomized, Controlled Trial , 2001, Circulation.
[30] M. Brignole,et al. Dual-chamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope : pacemaker versus no therapy: a multicenter randomized study. The Vasovagal Syncope International Study (VASIS) Investigators. , 2000, Circulation.
[31] Jun Li,et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association , 1999, The Lancet.
[32] M Gent,et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. , 1999, The New England journal of medicine.
[33] S. Connolly,et al. The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. , 1999, Journal of the American College of Cardiology.
[34] A. Wakefield,et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. , 1998, Lancet.
[35] J. Chmiel,et al. Sexual Adventurism, High‐Risk Behavior, and Human Immunodeficiency Virus‐1 Seroconversion Among the Chicago MACS‐CCS Cohort, 1984 to 1992: A Case‐Control Study , 1996, Sexually transmitted diseases.
[36] F Clerc,et al. Long-term results of valve replacement with the St. Jude Medical prosthesis. , 1995, The Journal of thoracic and cardiovascular surgery.
[37] F. R. Rosendaal,et al. Thromboembolic and Bleeding Complications in Patients With Mechanical Heart Valve Prostheses , 1994, Circulation.
[38] G. Friedman,et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. , 1992, The New England journal of medicine.
[39] J. Chmiel,et al. Seroconversion, sexual activity, and condom use among 2915 HIV seronegative men followed for up to 2 years. , 1989, Journal of acquired immune deficiency syndromes.
[40] P. Pinsky,et al. Public Health Service study of Reye's syndrome and medications. Report of the main study. , 1987, JAMA.
[41] R. Campbell,et al. Reye's Syndrome and Medication Use , 1982 .
[42] R. Waldman,et al. Aspirin as a risk factor in Reye's syndrome. , 1982, JAMA.
[43] K. Starko,et al. Reye's syndrome and salicylate use. , 1980, Pediatrics.
[44] I. Bross,et al. Pertinency of an extraneous variable. , 1967, Journal of chronic diseases.